HomeClinical TopicsFDA approves new treatment for relapsed follicular lymphoma
Clinical TopicsDrugs and DevicesNews

FDA approves new treatment for relapsed follicular lymphoma

follicular lymphoma fda treatment

On Sept. 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

Read More at FDA.gov

Previous articleGuideline for management of chronic pain in persons with HIV
Next articleFDA approves first biosimilar for treatment of cancer

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...

Powered by  HCM   www.HealthComMedia.com

© 2022 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.